<DOC>
	<DOCNO>NCT00154700</DOCNO>
	<brief_summary>The primary objective study find response rate twice weekly paclitaxel cisplatin weekly HDFL recurrent metastatic esophageal carcinoma patient need palliative Chemotherapy .</brief_summary>
	<brief_title>Twice Weekly TP-HDFL Recurrent Metastatic Esophageal Cancer</brief_title>
	<detailed_description>The primary objective study find response rate twice weekly paclitaxel cisplatin weekly HDFL recurrent metastatic esophageal carcinoma patient need palliative Chemotherapy . The secondary objective include overall survival , progression-free survival , toxicity .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Pathologically proven esophageal squamous cell adenocarcinoma Recurrence metastasis Measurable disease ( &gt; 1 X 1 cm ) CXR , CT scan MRI , Age &gt; 18 , KPS &gt; 60 % , Cre &lt; 1.5mg/dl , AST/ALT &lt; 3.5 X N , Bil &lt; 2.0mg/dl WBC &gt; 4,000/mm3 , ANC &gt; 2,000/ mm3 , Plt &gt; 100,000/mm3 Prior chemo ( except radiosensitizers ) Recurrent , treat esophageal lesion ( except &gt; 2 month )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>Combination , Chemotherapy , Esophageal Cancer</keyword>
</DOC>